RxDoctor Payments Data

Logan Kratt, MD

Family Medicine · Belton, MONPI 1467461558

Payments from drug & device makers

$12,861in general payments, 2019–2025

Across 752 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$937
  • Lilly USA, LLC$890
  • Pfizer$805
  • Boehringer Ingelheim$752
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$12,840100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,861 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$79,952
Medicare patients
272
Services billed
973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$154,624
EliquisApixaban122$117,072
OzempicSemaglutide52$68,595
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$58,142
MounjaroTirzepatide35$44,974
XareltoRivaroxaban40$35,697
LinzessLinaclotide33$32,326
TrulicityDulaglutide13$31,418
RexultiBrexpiprazole16$26,290
RybelsusSemaglutide13$25,595
JanuviaSitagliptin Phosphate24$25,023
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$23,322
MyrbetriqMirabegron34$22,466
FarxigaDapagliflozin Propanediol17$22,428
ArexvyRsvpref3 Antigen/As01e/Pf82$22,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$752$170,641132 claims
PfizerEliquis$805$117,072122 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$562$103,691185 claims
Novo NordiskOzempic, Rybelsus$937$94,19065 claims
Lilly USA, LLCMounjaro, Trulicity$890$76,39248 claims
Johnson & JohnsonXarelto$491$35,69740 claims
AbbVieLinzess$1,959$32,32633 claims
Otsuka America Pharmaceutical, Inc.Rexulti$237$26,29016 claims
MerckJanuvia$370$25,02324 claims
Astellas Pharma US IncMyrbetriq$153$22,46634 claims
AstraZenecaFarxiga$1,323$22,42817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Belton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →